Intas Builds Europe Scale With £603m Teva Deal
Executive Summary
Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.
You may also be interested in...
Time Is Of The Essence As Teva Considers European Assets Bids
Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.
Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A
Aurobindo Pharma reported a subdued Q1 but investors remained upbeat on the firm’s prospects as it transitions to a larger complex generics play. The company also emphasized its “disciplined” M&A approach; it has no interest in chasing “exotic” deals.
India Pharma 2017: 3Cs And D (Disruption)?
2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.